Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
October 03, 2018 09:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
September 20, 2018 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast this morning at 8:30 a.m. EDTJenrin’s extensive pipeline positions Corbus to be a leader in the treatment of inflammatory and fibrotic diseases with...